Vol. 19/No. 4

He was once laughed at for pouring his talent into the “reviled” field of oncology, but Larry Norton, MD, said he was driven by his passion to learn about cancer.

Investigators are looking into a combination of immunotherapy agents for patients with unresectable hepatocellular carcinoma, for whom there are limited treatment options in the first line.

Investigators looking for a superior means of testing for response to therapy in metastatic castration-resistant prostate cancer said they found the solution in a study of circulating tumor cells.

The past decade of drug discovery has brought a dramatic expansion in the number of new therapies to treat patients with advanced or metastatic melanoma in 2 modalities: checkpoint blockade immunotherapies and molecularly targeted drugs.

The use of next-generation sequencing to diagnose cancers and guide therapy decisions is expanding as more therapies are linked to genomic abnormalities.

A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.

Advanced interventional pulmonology techniques are revolutionizing the diagnosis and treatment of lung cancer.

Decision support is only lightly touched upon in the academic oncology papers that are published almost daily suggesting a potential change in paradigms for management in a particular clinical setting.